This document discusses important privacy issues related to sharing health information electronically. It identifies the key questions that must be answered to determine sharing requirements, such as who is sharing what information with whom and for what purpose. It also outlines important privacy issues like HIPAA compliance, mobile devices, and coordination with security. Specific issues for health information exchanges are discussed, including mental health, substance abuse, and public trust.
Michigan Health Information Network Shared Services MiHIN ADT Admit Discharge Transfer ONC Office of the National Coordinator for Health Information Technolgy HIT HIE
Michigan Health Information Network Shared Services MiHIN ADT Admit Discharge Transfer ONC Office of the National Coordinator for Health Information Technolgy HIT HIE
HOT NEW PRODUCT! BIG SALES FAST SHIPPING NOW FROM CHINA!! EU KU DB BK substit...GL Anaacs
Contact us if you are interested:
Email / Skype : kefaya1771@gmail.com
Threema: PXHY5PDH
New BATCH Ku !!! MUCH IN DEMAND FAST SALE EVERY BATCH HAPPY GOOD EFFECT BIG BATCH !
Contact me on Threema or skype to start big business!!
Hot-sale products:
NEW HOT EUTYLONE WHITE CRYSTAL!!
5cl-adba precursor (semi finished )
5cl-adba raw materials
ADBB precursor (semi finished )
ADBB raw materials
APVP powder
5fadb/4f-adb
Jwh018 / Jwh210
Eutylone crystal
Protonitazene (hydrochloride) CAS: 119276-01-6
Flubrotizolam CAS: 57801-95-3
Metonitazene CAS: 14680-51-4
Payment terms: Western Union,MoneyGram,Bitcoin or USDT.
Deliver Time: Usually 7-15days
Shipping method: FedEx, TNT, DHL,UPS etc.Our deliveries are 100% safe, fast, reliable and discreet.
Samples will be sent for your evaluation!If you are interested in, please contact me, let's talk details.
We specializes in exporting high quality Research chemical, medical intermediate, Pharmaceutical chemicals and so on. Products are exported to USA, Canada, France, Korea, Japan,Russia, Southeast Asia and other countries.
HOT NEW PRODUCT! BIG SALES FAST SHIPPING NOW FROM CHINA!! EU KU DB BK substit...GL Anaacs
Contact us if you are interested:
Email / Skype : kefaya1771@gmail.com
Threema: PXHY5PDH
New BATCH Ku !!! MUCH IN DEMAND FAST SALE EVERY BATCH HAPPY GOOD EFFECT BIG BATCH !
Contact me on Threema or skype to start big business!!
Hot-sale products:
NEW HOT EUTYLONE WHITE CRYSTAL!!
5cl-adba precursor (semi finished )
5cl-adba raw materials
ADBB precursor (semi finished )
ADBB raw materials
APVP powder
5fadb/4f-adb
Jwh018 / Jwh210
Eutylone crystal
Protonitazene (hydrochloride) CAS: 119276-01-6
Flubrotizolam CAS: 57801-95-3
Metonitazene CAS: 14680-51-4
Payment terms: Western Union,MoneyGram,Bitcoin or USDT.
Deliver Time: Usually 7-15days
Shipping method: FedEx, TNT, DHL,UPS etc.Our deliveries are 100% safe, fast, reliable and discreet.
Samples will be sent for your evaluation!If you are interested in, please contact me, let's talk details.
We specializes in exporting high quality Research chemical, medical intermediate, Pharmaceutical chemicals and so on. Products are exported to USA, Canada, France, Korea, Japan,Russia, Southeast Asia and other countries.
- Video recording of this lecture in English language: https://youtu.be/lK81BzxMqdo
- Video recording of this lecture in Arabic language: https://youtu.be/Ve4P0COk9OI
- Link to download the book free: https://nephrotube.blogspot.com/p/nephrotube-nephrology-books.html
- Link to NephroTube website: www.NephroTube.com
- Link to NephroTube social media accounts: https://nephrotube.blogspot.com/p/join-nephrotube-on-social-media.html
These lecture slides, by Dr Sidra Arshad, offer a quick overview of physiological basis of a normal electrocardiogram.
Learning objectives:
1. Define an electrocardiogram (ECG) and electrocardiography
2. Describe how dipoles generated by the heart produce the waveforms of the ECG
3. Describe the components of a normal electrocardiogram of a typical bipolar leads (limb II)
4. Differentiate between intervals and segments
5. Enlist some common indications for obtaining an ECG
Study Resources:
1. Chapter 11, Guyton and Hall Textbook of Medical Physiology, 14th edition
2. Chapter 9, Human Physiology - From Cells to Systems, Lauralee Sherwood, 9th edition
3. Chapter 29, Ganong’s Review of Medical Physiology, 26th edition
4. Electrocardiogram, StatPearls - https://www.ncbi.nlm.nih.gov/books/NBK549803/
5. ECG in Medical Practice by ABM Abdullah, 4th edition
6. ECG Basics, http://www.nataliescasebook.com/tag/e-c-g-basics
micro teaching on communication m.sc nursing.pdfAnurag Sharma
Microteaching is a unique model of practice teaching. It is a viable instrument for the. desired change in the teaching behavior or the behavior potential which, in specified types of real. classroom situations, tends to facilitate the achievement of specified types of objectives.
MANAGEMENT OF ATRIOVENTRICULAR CONDUCTION BLOCK.pdfJim Jacob Roy
Cardiac conduction defects can occur due to various causes.
Atrioventricular conduction blocks ( AV blocks ) are classified into 3 types.
This document describes the acute management of AV block.
Tom Selleck Health: A Comprehensive Look at the Iconic Actor’s Wellness Journeygreendigital
Tom Selleck, an enduring figure in Hollywood. has captivated audiences for decades with his rugged charm, iconic moustache. and memorable roles in television and film. From his breakout role as Thomas Magnum in Magnum P.I. to his current portrayal of Frank Reagan in Blue Bloods. Selleck's career has spanned over 50 years. But beyond his professional achievements. fans have often been curious about Tom Selleck Health. especially as he has aged in the public eye.
Follow us on: Pinterest
Introduction
Many have been interested in Tom Selleck health. not only because of his enduring presence on screen but also because of the challenges. and lifestyle choices he has faced and made over the years. This article delves into the various aspects of Tom Selleck health. exploring his fitness regimen, diet, mental health. and the challenges he has encountered as he ages. We'll look at how he maintains his well-being. the health issues he has faced, and his approach to ageing .
Early Life and Career
Childhood and Athletic Beginnings
Tom Selleck was born on January 29, 1945, in Detroit, Michigan, and grew up in Sherman Oaks, California. From an early age, he was involved in sports, particularly basketball. which played a significant role in his physical development. His athletic pursuits continued into college. where he attended the University of Southern California (USC) on a basketball scholarship. This early involvement in sports laid a strong foundation for his physical health and disciplined lifestyle.
Transition to Acting
Selleck's transition from an athlete to an actor came with its physical demands. His first significant role in "Magnum P.I." required him to perform various stunts and maintain a fit appearance. This role, which he played from 1980 to 1988. necessitated a rigorous fitness routine to meet the show's demands. setting the stage for his long-term commitment to health and wellness.
Fitness Regimen
Workout Routine
Tom Selleck health and fitness regimen has evolved. adapting to his changing roles and age. During his "Magnum, P.I." days. Selleck's workouts were intense and focused on building and maintaining muscle mass. His routine included weightlifting, cardiovascular exercises. and specific training for the stunts he performed on the show.
Selleck adjusted his fitness routine as he aged to suit his body's needs. Today, his workouts focus on maintaining flexibility, strength, and cardiovascular health. He incorporates low-impact exercises such as swimming, walking, and light weightlifting. This balanced approach helps him stay fit without putting undue strain on his joints and muscles.
Importance of Flexibility and Mobility
In recent years, Selleck has emphasized the importance of flexibility and mobility in his fitness regimen. Understanding the natural decline in muscle mass and joint flexibility with age. he includes stretching and yoga in his routine. These practices help prevent injuries, improve posture, and maintain mobilit
ARTIFICIAL INTELLIGENCE IN HEALTHCARE.pdfAnujkumaranit
Artificial intelligence (AI) refers to the simulation of human intelligence processes by machines, especially computer systems. It encompasses tasks such as learning, reasoning, problem-solving, perception, and language understanding. AI technologies are revolutionizing various fields, from healthcare to finance, by enabling machines to perform tasks that typically require human intelligence.
Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists Saeid Safari
Preoperative Management of Patients on GLP-1 Receptor Agonists like Ozempic and Semiglutide
ASA GUIDELINE
NYSORA Guideline
2 Case Reports of Gastric Ultrasound
These simplified slides by Dr. Sidra Arshad present an overview of the non-respiratory functions of the respiratory tract.
Learning objectives:
1. Enlist the non-respiratory functions of the respiratory tract
2. Briefly explain how these functions are carried out
3. Discuss the significance of dead space
4. Differentiate between minute ventilation and alveolar ventilation
5. Describe the cough and sneeze reflexes
Study Resources:
1. Chapter 39, Guyton and Hall Textbook of Medical Physiology, 14th edition
2. Chapter 34, Ganong’s Review of Medical Physiology, 26th edition
3. Chapter 17, Human Physiology by Lauralee Sherwood, 9th edition
4. Non-respiratory functions of the lungs https://academic.oup.com/bjaed/article/13/3/98/278874
New Directions in Targeted Therapeutic Approaches for Older Adults With Mantl...i3 Health
i3 Health is pleased to make the speaker slides from this activity available for use as a non-accredited self-study or teaching resource.
This slide deck presented by Dr. Kami Maddocks, Professor-Clinical in the Division of Hematology and
Associate Division Director for Ambulatory Operations
The Ohio State University Comprehensive Cancer Center, will provide insight into new directions in targeted therapeutic approaches for older adults with mantle cell lymphoma.
STATEMENT OF NEED
Mantle cell lymphoma (MCL) is a rare, aggressive B-cell non-Hodgkin lymphoma (NHL) accounting for 5% to 7% of all lymphomas. Its prognosis ranges from indolent disease that does not require treatment for years to very aggressive disease, which is associated with poor survival (Silkenstedt et al, 2021). Typically, MCL is diagnosed at advanced stage and in older patients who cannot tolerate intensive therapy (NCCN, 2022). Although recent advances have slightly increased remission rates, recurrence and relapse remain very common, leading to a median overall survival between 3 and 6 years (LLS, 2021). Though there are several effective options, progress is still needed towards establishing an accepted frontline approach for MCL (Castellino et al, 2022). Treatment selection and management of MCL are complicated by the heterogeneity of prognosis, advanced age and comorbidities of patients, and lack of an established standard approach for treatment, making it vital that clinicians be familiar with the latest research and advances in this area. In this activity chaired by Michael Wang, MD, Professor in the Department of Lymphoma & Myeloma at MD Anderson Cancer Center, expert faculty will discuss prognostic factors informing treatment, the promising results of recent trials in new therapeutic approaches, and the implications of treatment resistance in therapeutic selection for MCL.
Target Audience
Hematology/oncology fellows, attending faculty, and other health care professionals involved in the treatment of patients with mantle cell lymphoma (MCL).
Learning Objectives
1.) Identify clinical and biological prognostic factors that can guide treatment decision making for older adults with MCL
2.) Evaluate emerging data on targeted therapeutic approaches for treatment-naive and relapsed/refractory MCL and their applicability to older adults
3.) Assess mechanisms of resistance to targeted therapies for MCL and their implications for treatment selection
3. To identify what requirements must be
met to share information, ask:
• Who is sharing
• What
information
• With whom
• For what purpose
4. Important Privacy Issues:
• HIPAA & Other Compliance
Initiatives
• Mobile Devices
• Coordination with Security
5. Important Privacy Issues in the HIE
Context:
• Mental Health & Substance Abuse
• Public Trust & Buy-in
Editor's Notes
Introduction – My role as an attorney at MDCH is to advise staff on privacy issues across all of the Department’s programs, which include the Medicaid program, public health activities and programs, as well as behavioral health, substance abuse, and developmental disabilities programs. MDCH is one of the largest state government agencies, and is responsible for health policy and management of the state's publicly-funded health service systems.About 2 million Michigan residents will receive services this year that are provided with total or partial support from MDCH.MDCH has 2013 total funding of $15 billion and approximately 3,100 employees. Working on HIE issues is one small subset of the work I do for the Department.
A quick disclaimer - I’m an attorney and DCH is my client. I advise DCH on how it might share information through its data hub to MiHIN and on other legal issues. But I can’t advise other individuals or organizations outside of DCH because they are not my clients. But I can share with you my perspective on privacy issues.
Figuring out the relationship between entities that want to share data and the technical infrastructure supporting that data sharing can get really abstract and complicated. I try to simplify things with the following analysis:Asking “who” helps identify the obligations that entity might have. For example, under HIPAA, DCH is a hybrid covered entity. So HIPAA applies to some offices within DCH when sharing protected health information and HIPAA doesn’t apply to other offices within DCH when sharing information.Asking “what information” is the key question because that question leads us to what laws might protect the confidentiality of the information. And those laws also describe how that information might be shared and what authorization might be needed. Asking “with whom” allows us to discover whether we can share the information with that entity given the confidential protections. The information might be used internally and therefore there might be few if any limits how it might be shared. Under HIPAA, we know that info can be shared without patient authorization by a covered entity to another covered entity or a provider if the information is disclosed for treatment, payment, or health care operations. On the other hand, if the protected health information is disclosed to a business associate of a covered entity, then there are other legal obligations on the business associate for protecting the confidentiality of the information.Asking “for what purpose” allows me to determine whether the information can be shared consistent with any applicable confidentiality laws. For example, HIPAA has specific exceptions, like public health, research, and others, that allow for the disclosure of PHI.
HIPAA & Other Compliance:As many of you probably know, the Office for Civil Rights has been ramping up its HIPAA enforcement and audit activities. It’s really important now to properly document your organization’s compliance so that you do not face millions of dollars in penalties from OCR. I was at a conference earlier this year, and one of the speakers from OCR discussed the results of recent HIPAA compliance audits. OCR audited a range of entities – from large hospitals to small providers. Only 11% of the 115 entities audited as of Dec 2012 had no findings. By compliance I mean the proper legal agreements in place, documenting business flows and processes, documenting policies and procedures regarding information privacy and security, and training of staff members. Given the culture of enforcement at OCR, it is extremely important to evaluate internally compliance with HIPAA on a periodic basis. By other compliance, I mean that it is also important to take similar steps to document policies, procedures, training, etc for other confidentiality laws that may apply to your practice or organization – for example, HIV/AIDS data, mental health, substance abuse, and so on.Mobile Devices:The increased use of mobile devices – laptops, smart phones, and even jump drives – allows us to have more flexibility in where and when we work, but it also increases the potential for an unauthorized use or disclosure of PHI or other confidential information. For example, OCR has published a list of the top five compliance issues over the last decade, and from 2004-2010 (last year published) the number one compliance issue was impermissible uses and disclosures. Mobile devices increase the risk of an unauthorized disclosure because they are out and about with us, and they can easily be lost or stolen, creating additional opportunities for unauthorized access to confidential information. Coordination with Security:To me, privacy and security are separate but interrelated concepts and functions. I agree with the errors that Dan identified, especially the one about basing security on systems rather than on the critical data. Privacy laws can help identify the critical data elements that have to be protected from use or disclosure in some way, and security, from a technological standpoint, can provide the solution to accomplish protecting the data (encryption, role-based access, authentication, etc.). Security solutions may go further than what HIPAA or other privacy laws require for compliance. The point is that privacy and security staff within an organization need to work together to accomplish protecting the privacy rights of individual’s information, as well as the security and integrity of the data itself.
Mental Health & Substance Abuse:I participate in MiHIN’s privacy work group, and one of the issues we are working through is how mental health and substance abuse information, both of which have more stringent privacy protections than HIPAA, will be utilized through HIE technology. How is consent managed? Where are documents stored? Who is liable? This is also an issue for any information that is protected by laws that are more stringent than HIPAA.Public Trust & Buy-in:I heard another speaker at the conference I mentioned that I attended earlier this year who spoke about privacy as an “enabler” to the flow of information. What I think she meant by this is that if the public does not trust the HIE system, they might engage in “privacy-protective” behavior. For example, they might opt-out altogether or they might not allow all of their health information to be disclosed to a provider. This could have real consequences in terms of the quality of medical care – just like withholding information from a doctor about drug use or prescriptions can compromise that providers ability to treat you. Public education and knowledge about how the HIE functions, how their information might be shared, the privacy and security protections in place will help to build the public’s trust and minimize “privacy-protective” behavior.
